Summary
Global Markets Direct’s, ‘Redx Pharma Plc - Product Pipeline Review - 2016’, provides an overview of the Redx Pharma Plc’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Redx Pharma Plc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Redx Pharma Plc
- The report provides overview of Redx Pharma Plc including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Redx Pharma Plc’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Redx Pharma Plc’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Redx Pharma Plc’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Redx Pharma Plc
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Redx Pharma Plc’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Redx Pharma Plc Snapshot 5
Redx Pharma Plc Overview 5
Key Information 5
Key Facts 5
Redx Pharma Plc - Research and Development Overview 6
Key Therapeutic Areas 6
Redx Pharma Plc - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Redx Pharma Plc - Pipeline Products Glance 13
Redx Pharma Plc - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
Redx Pharma Plc - Drug Profiles 15
RDX-001 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
RDX-002 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
RDX-003 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
RDX-004 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Small Molecules to Inhibit cFMS Kinase for Immunology and Oncology 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Small Molecules to Inhibit DNA Gyrase for Neisseria Gonorrhoeae Infections 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Small Molecules for Bacterial Infections 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Small Molecules for Hepatitis B 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Small Molecules for Oncology 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Small Molecules to Inhibit IDO for Solid Tumors 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Small Molecules to Inhibit Neuraminidase for Influenza A and B Infections 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Small Molecules to Inhibit Pan-Raf Kinases for Colorectal Cancer 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Redx Pharma Plc - Pipeline Analysis 27
Redx Pharma Plc - Pipeline Products by Target 27
Redx Pharma Plc - Pipeline Products by Route of Administration 28
Redx Pharma Plc - Pipeline Products by Molecule Type 29
Redx Pharma Plc - Pipeline Products by Mechanism of Action 30
Redx Pharma Plc - Recent Pipeline Updates 31
Redx Pharma Plc - Dormant Projects 32
Redx Pharma Plc - Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 34
Disclaimer 35
List of Tables
Redx Pharma Plc, Key Information 5
Redx Pharma Plc, Key Facts 5
Redx Pharma Plc - Pipeline by Indication, 2016 7
Redx Pharma Plc - Pipeline by Stage of Development, 2016 9
Redx Pharma Plc - Monotherapy Products in Pipeline, 2016 10
Redx Pharma Plc - Partnered Products in Pipeline, 2016 11
Redx Pharma Plc - Partnered Products/ Combination Treatment Modalities, 2016 12
Redx Pharma Plc - Preclinical, 2016 13
Redx Pharma Plc - Discovery, 2016 14
Redx Pharma Plc - Pipeline by Target, 2016 27
Redx Pharma Plc - Pipeline by Route of Administration, 2016 28
Redx Pharma Plc - Pipeline by Molecule Type, 2016 29
Redx Pharma Plc - Pipeline Products by Mechanism of Action, 2016 30
Redx Pharma Plc - Recent Pipeline Updates, 2016 31
Redx Pharma Plc - Dormant Developmental Projects,2016 32
Redx Pharma Plc, Other Locations 33
Redx Pharma Plc, Subsidiaries 33
List of Figures
Redx Pharma Plc - Pipeline by Top 10 Indication, 2016 7
Redx Pharma Plc - Pipeline by Stage of Development, 2016 9
Redx Pharma Plc - Monotherapy Products in Pipeline, 2016 10
Redx Pharma Plc - Partnered Products in Pipeline, 2016 11
Redx Pharma Plc - Pipeline by Top 10 Target, 2016 27
Redx Pharma Plc - Pipeline by Route of Administration, 2016 28
Redx Pharma Plc - Pipeline by Molecule Type, 2016 29
Redx Pharma Plc - Pipeline Products by Top 10 Mechanism of Action, 2016 30
